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Emerging Governance of Mitochondrial Replacement Therapy: Assessing Coherence Between
Scientific Evidence and Policy Outcomes
I. Introduction
In the fall of 2016, media headlines reported news of the first baby born as a result of
what has been called “three parent IVF” or mitochondrial replacement therapy (“MRT”).1 The
initial report indicated Dr. John Zhang, of the New York New Hope Fertility Center worked with
a couple from Jordan and traveled to Mexico to perform a procedure called maternal spindle
transfer.2 New Scientist first described the “great news” of the first known birth of the child born
to the Jordanian couple at risk for mitochondrial disease.3 Reports asserted the infant “appeared
to be healthy,” but did not provide substantive evaluation of the infant.4
Science Magazine characterized this transnational arrangement as a means for desperate
parents who wish to bear a genetically related child free from fatal genetic disease.5 Media
described MRT as a technique that allows parents with rare genetic mutations “to have healthy
babies” because it constitutes a “treatment, or even a cure” and praised the courageous Dr. Zhang
as a pioneer whose work “should fast-forward progress” against regulatory barriers in the United

Jessica Hamzelou, World’s First Baby Born With New “3 Parent” Technique, NEW SCIENTIST
(Sept. 27, 2016), https://www.newscientist.com/article/2107219-exclusive-worlds-first-babyborn-with-new-3-parent-technique/; Jennifer Couzin-Frankel, Unanswered Questions Surround
Baby Born to Three Parent, SCIENCE (Sept. 27, 2016),
http://www.sciencemag.org/news/2016/09/unanswered-questions-surround-baby-born-threeparents.
2
Id.
3
Id.
4
Couzin-Frankel, supra note 1; see also Sara Reardon, Reports of “Three-Parent Babies”
Multiply, NATURE NEWS (Oct. 19, 2016), http://www.nature.com/news/reports-of-three-parentbabies-multiply-1.20849.
5
Id.
1
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States. 6 One stem cell biologist asserted regulatory barriers have “[put] novel treatments on the
long bench, and therefore it had to be done that way.” 7 The British Broadcasting Corporation
(BBC) praised Dr. Zhang as acting ethically on his mission to “save lives” and assist families in
need of treatment.8
Weeks later, more reports surfaced that Dr. Valery Zukin, a physician in Kiev, Ukraine
used MRT to “treat” general infertility for two patients in his clinic.9 Similar to descriptions of
Dr. Zhang’s actions, Nature reported during the pregnancies that Dr. Zukin’s technique “seems
to have fixed the problem” on the premise that the pregnancy continued to progress.10 Months
later following the birth of the first infant, the media repeated the claim of good news, asserting
that after fifteen years of infertility, the patient in Dr. Zukin’s clinic finally gave birth to a
“healthy baby” that is genetically her own.11
MRT described in this article currently refers to two procedures. In the first procedure,
maternal spindle transfer (“MST:), the nucleus in the mother’s oocyte is removed and transferred

Id.; Alexandra Ossola, FDA Expected to Approve Technique to Create “The Three-Parent
Babies,” POPULAR SCIENCE (Feb. 3, 2016), http://www.popsci.com/fda-approves-technique-tocreate-three-parent-babies.
7
Reardon, supra note 4.
8
Michelle Roberts, First “Three Person Baby” Born Using New Method, BBC NEWS (Sept. 27,
2016), http://www.bbc.com/news/health-37485263.
9
Andy Coghlan, “3-Parent” Baby Method Already Used for Infertility, NEW SCIENTIST (Oct. 10,
2016), https://www.newscientist.com/article/2108549-exclusive-3-parent-baby-method-alreadyused-for-infertility/.
10
Reardon, supra note 4; see also Andy Coghlan, First Baby Born Using 3-Parent Technique to
Treat Infertility, NEW SCIENTIST (Jan. 18, 2017), https://www.newscientist.com/article/2118334first-baby-born-using-3-parent-technique-to-treat-infertility/.
11
59th MEETING OF THE CELLULAR, TISSUE, AND GENE THERAPIES ADVISORY COMMITTEE, FDA
(Feb. 25, 2014),
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVacci
nesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM390945.pdf at
19-21 [hereinafter “FDA Meeting”].
6
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into a donor oocyte whereby the donor oocyte is subsequently fertilized.12 The second method is
referred to as pronuclear transfer (“PNT”), where both the mother’s oocyte is fertilized and the
donor oocyte is fertilized with sperm in vitro, which creates two zygotes. The nucleus from the
fertilized donor zygote is removed and is then replaced with the nucleus from the mother’s stage
matched zygote.13 These experimental techniques that promise to “swap in healthy
mitochondria” have come under additional scrutiny because MRT entails nuclear genome
transfer, which constitutes a modification of the germline that breaches the historical bright line
of impermissible interventions on human embryos used for implantation.14
Despite a number of international agreements and criminal prohibitions against germline
modification in other countries abroad, there is no such legal prohibition in the United States.15
Last year in the United Kingdom, the Human Fertilisation and Embryology Authority announced
it would begin reviewing license applications from fertility clinics that wished to offer MRT to
patients as a means to avoid mitochondrial disease. In the United States, the FDA has discussed
scientific considerations and the National Academy of Sciences, Engineering, and Medicine

12

Id.
Rosa Castro, Mitochondrial Replacement Therapy: the U.K. and US Regulatory Landscapes, 3
J. OF L. & THE BIOSCIENCES 726, 728 (2016); FDA Briefing Document: Oocyte Modification in
Assisted Reproduction for the Prevention of Transmission of Mitochondrial Disease or the
Treatment of Infertility, CELLULAR, TISSUE, & GENE THERAPIES ADVISORY COMM., FDA (Feb.
25-26, 2014) [hereinafter “FDA Brief”]; Mitochondrial Replacement Techniques: Ethical,
Social, and Policy Considerations, NAT’L ACADS. OF SCI. ENG’G & MED. at 20-21 (2016)
[hereinafter “NAS Report”].
14
FDA Should Preserve International Consensus Against Human Germline Modifications,
Center for Genetics and Society (Feb. 19, 2014),
http://www.geneticsandsociety.org/article.php?id=7528.
15
Tetsuya Ishii, Potential Impact of Human Mitochondrial Replacement on Global Policy
Regarding Germline Gene Modification, 29 REPROD. BIOMEDICINE ONLINE 150, 152-53 (2014);
Motoko Araki & Tetsuya Ishii, International Regulatory Landscape and Integration of
Corrective Genome Editing Into In Vitro Fertilization, 12 REPROD. BIOLOGY & ENDOCRINOLOGY
9 (2014); Rosario Isasi et al., Editing Policy to Fit the Genome? 351 SCIENCE 337 (2016).
13
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concluded it is ethically permissible to conduct clinical investigations subject to a set of
conditions. Notably, FDA discussions have not only considered MRT as a potential
investigational method for treating mtDNA disease, but also as an option for treating infertility.
Drawing upon the process in the U.K., this article examines the regulatory framework
developed in the U.K., contrasts this system with nations that prohibit or criminalize germline
interventions, and describes the regulatory and policymaking discussions that have occurred in
the United States. In response to the recent amendments to the law in the U.K. and current
reproductive tourism for MRT, this article will describe efforts at public engagement during the
policymaking process and the ethical divide pertaining to germline modifications. This article
will synthesize the currently known scientific considerations pertaining to safety, efficacy, and
risk related to mitochondrial biology, oocyte modification, and oocyte donation. Finally, the
article will evaluate the medical rationale provided by proponents that such technology is both
necessary and beneficial and consider the impact of commercial interests on the development of
MRT.
II. Primer on Mitochondrial Biology
Mitochondria are organelles found in almost every cell in the human body and serve a
number of functions including energy production, controlling metabolic processes, and
programming cell growth and apoptosis.16 Far from being mere “batteries” of the cell, scientists
now recognize extensive interaction between mitochondrial DNA (“mtDNA”) and nuclear DNA

16

FDA Brief, supra note 13, at 5; Anne Claiborne et al., Finding an Ethical Path Forward for
Mitochondrial Replacement, 351 SCIENCE 668 (2016); Kimberly Dunham-Snary & Scott
Ballinger, Mitochondrial-Nuclear DNA Mismatch Matters, 349 SCIENCE 1449 (2015); Eli Adashi
& I. Glenn Cohen, Going Germline: Mitochondrial Replacement as a Guide to Genome Editing,
164 CELL 832 (2016).
4

(“nDNA”) that directly impacts gene expression and cell function.17 Mitochondria are
maternally inherited, and pathogenic mutations in mtDNA can present as a number of serious
and potentially fatal diseases.18 Mitochondrial dysfunction may result in a variety of disorders
affecting tissues with a high metabolic demand, such as the brain, heart, muscle, and central
nervous system.19
Although many individuals in the population may carry mtDNA mutations, these
mutations will not result in dysfunction unless the percent of mutant mitochondria reaches a
particular threshold.20 Currently, in the process of both MST and PNT a small percent of
cytoplasm is transferred along with the nucleus during the nuclear genome transfer from the
mother’s oocyte or zygote into the donor’s.21 Although the rate of carryover of mtDNA has been
reportedly low, scientists believe the percent of the mother’s mutated mtDNA could increase.22
Scientists refer to the percent mix of mutant mitochondria as degree of heteroplasmy.23 When
cells divide during embryogenesis, gametogenesis, and during the course of normal
development, the levels of mutant mitochondria may increase in the dividing cells, which can
lead to differential replication and segregation toward a higher degree of heteroplasmy, even in

17

FDA Brief, supra note 13, at 5; FDA Meeting, supra note 11, at 18, 24-31; Klaus Reinhardt et
al., Mitochondrial Replacement, Evolution, and the Clinic, 341 SCIENCE 1345, 1346.
(2013)(discussing the impact of mtDNA on nDNA expression and cross-talk between mtDNA
and nDNA).
18
FDA Brief, supra note 13, at 8.
19
Paula Amato et al., Three Parent In Vitro Fertilization: Gene Replacement for the Prevention
of Inherited Mitochondrial Disease, 101 FERTILITY & STERILITY 31 (2014).
20
FDA Meeting, supra note 11, at 34-41 (discussing heteroplasmy and disease threshold) and at
66 (hypothesis that we all have naturally occurring heteroplasmy).
21
FDA Meeting, supra note 11, at 21, 123, 168; FDA Brief, supra note 13, at 14-15, 20; NAS
Report, supra note 13, at 47.
22
FDA Meeting, supra note 11, at 34-41
23
Id.
5

varying levels through different tissues in the body. 24 Scientists describe a phenomenon referred
to as maternal bottleneck, defined as when levels of heteroplasmy increase from one generation
to the next.25 For example, a mother with a low level of heteroplasmy who may not display signs
of mitochondrial dysfunction and appears healthy could give birth to a child with a high level of
heteroplasmy that would reach the threshold and present as mitochondrial disease.26
Mitochondrial disease can arise from either mtDNA mutations or nDNA mutations,
though inherited mtDNA mutations are rare. According to evidence presented at the Cellular,
Tissue, and Gene Therapies Advisory Committee meeting in 2014, maternal transmission of
mtDNA disease is rare and only occurs in 1/10,000 individuals.27 This distinction provides
crucial perspective, because failing to distinguish between maternally inherited mtDNA disease
and nDNA mitochondrial disease can skew public perceptions of statistical occurrence in a
misleading manner. During the public engagement process in the U.K., Human Fertilisation and
Embryology Authority characterized the frequency of mitochondrial mutations as affecting 1/200
individuals, and one headline proclaimed nearly 2500 women could benefit from MRT in the
U.K.28 Yet these figures omitted discerning between mtDNA disease and mitochondrial disease
resulting from nDNA mutations.29 Most cases of mitochondrial disease arise from de novo

24

Id.
Id. at 34-35.
26
Id. at 132-35.
27
Id. at 64.
28
Human Genetic Engineering on the Doorstep, HUMAN GENETICS ALERT (Nov. 2012) at 4,
http://www.hgalert.org/Mitochondria%20briefing.pdf; Nearly 2,500 Women Could Benefit from
Mitochondrial Donation in the U.K., SCIENCE DAILY (Jan. 29, 2015),
https://www.sciencedaily.com/releases/2015/01/150129094353.htm.
29
See Francoise Baylis, The Ethics of Creating Children With Three Genetic Parents, 26
REPROD. BIOMEDICINE ONLINE 531 (2013).
25
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mutations (new mutations in mtDNA not present in the maternal line) and mutations in nDNA.30
Approximately 80% of mitochondrial disease arises from nDNA mutations, for which MRT does
not address.31 When subtracting the incidence of nDNA disease, the final potential pool of cases
where MRT may apply falls to ten persons a year for the population cited in the discussion
pertaining to the U.K.32
There is currently no FDA approved treatment for mitochondrial disease.33 Literature has
discussed potential alternative methods designed to avoid mitochondrial disease: adoption, preimplantation genetic diagnosis (“PGD”), and use of an oocyte donor.34 Some scholars have
rejected adoption and use of an oocyte donor because it overlooks parental desire to bear a
genetically related child.35 PGD may reduce, but not eliminate the chance for a child without
mitochondrial disease based on uncertainty of whether the subsequent cellular division would
result in genetic drift, defined as increasing rates of mutant DNA and heteroplasmy that reaches
the threshold for disease.36

30

FDA Meeting, supra note 11, at 58-64; see also NAS Report, supra note 13, at 27 (discussing
mtDNA disease generally relating to later onset milder conditions and nDNA disease
constituting earlier onset and more severe expressivity).
31
Third Scientific Review of the Safety and Efficacy of Methods to Avoid Mitochondrial Disease
Through Assisted Conception: 2014 Update, HUM. FERTILISATION & EMBRYOLOGY AUTH. at 12
(June 2014) [hereinafter “HFEA Scientific Review”].
32
Ishii, supra note 15, at 151; Mitochondrial Donation: Correspondence Received Relating to
the Evidence Hearing on 22 October 2014, SCI. & TECH. COMM., HOUSE OF COMMONS at 15
(2014), https://www.parliament.U.K./documents/commons-committees/sciencetechnology/Mitochondrial%20donation/MITCorrespondence.pdf [hereinafter “U.K.
Correspondence”].
33
FDA Brief, supra note 13, at 9.
34
Baylis, supra note 29; FDA Brief, supra note, at 10.
35
Sarah Fogleman et al., CRISPR/Cas9 and Mitochondrial Replacement Therapy: Promising
Techniques and Ethical Considerations, 5 AM. J. OF STEM CELLS 39 (2016).
36
Amato et al., supra note 19, at 32.
7

III. International Law and Policy Pertaining to Germline Modification
Contrary to the common parlance discussing the procedure, MRT does not replace
mitochondria or “swap in healthy mitochondria,” but instead constitutes transferring the nucleus
containing 20,000 genes from one oocyte or zygote to another.37 This procedure is more
accurately classified as nuclear genome transfer and a modification of the human germline,
which has prohibited by numerous declarations, directives, and laws promulgated by
international entities and other nations.38
A. United Nations Position on Germline Modification
The United Nations Universal Declaration on the Human Genome and Human Rights has
declared that the “human genome underlies the fundamental unity of all member of the human
family…it is the heritage of humanity.”39 In Article 5, the Declaration states “research,
diagnosis, or treatment affecting an individual’s genome shall be undertaken only after rigorous
and prior assessment of potential risks and benefits,” this intervention requires informed consent
that the procedure would be guided by the individual’s best interest, and if the individual does
not have the capacity to consent then the intervention may only be carried out for the direct
benefit or, alternatively, “pose such minimal risk and burden” to the individual that the research
is “compatible with the protection of the individual’s human rights.”40 These articles do not
distinguish between somatic and germline interventions, but suggest a high level of scrutiny

37

3-Person IVF A Resource Page, CTR. FOR GENETICS AND SOCIETY,
http://www.geneticsandsociety.org/article.php?id=6527.
38
Id.; Isasi et al., supra note 15; Ishii, supra note 15; Araki & Ishii, supra note 15.
39
Universal Declaration on the Human Genome and Human Rights, UNITED NATIONS SCI.
EDUC., SCI. & CULTURAL ORG., UNITED NAT’L GEN. ASSEMB. (1997),
http://www.unesco.org/new/en/social-and-human-sciences/themes/bioethics/human-genomeand-human-rights/.
40
Id.
8

regarding risks must be applied in this area of research and individual consent must be
prioritized. These points interpreted together would likely prohibit germline engineering based
both on the risk profile and inability for future generations to consent to modification of their
genomes.
In subsequent discussions specifically pertaining to the human genome and the
appropriate uses of emerging technology, the International Bioethics Committee of the United
Nations Educational, Scientific, and Cultural Organization (“UNESCO”) promulgated additional
guiding principles.41 Importantly, the International Bioethics Committee noted that the human
genome does not constitute raw material that scientists may manipulate at leisure, cautions
against genetic reductionism and parsing component parts when attempting to treat the complex
nature of human disease while noting the uncertain and highly variable state of the genome and
the unpredictable impact of modifications.42 Recognizing the transnational nature of research, the
International Bioethics Committee also directly stated that we should renounce the possibility of
scientists acting alone and discourage avenues of regulatory circumvention, in this instance,
through reproductive tourism.43 Finally, the International Bioethics Committee called upon the
media to avoid sensationalist journalism, asserted the media’s duty to promote scientific literacy,
and cautioned that the direction and limitations of science should not be determined by market
forces.44
Together, these crucial points recognize the complexities of human health and appear to

41

Report of the IBC on Updating Its Reflection on the Human Genome and Human Rights,
UNITED NATIONS SCI. EDUC., SCI. & CULTURAL ORG., UNITED NAT’L GEN. ASSEMB. (2015),
http://unesdoc.unesco.org/images/0023/002332/233258E.pdf.
42
Id. at 4.
43
Id. at 3-4.
44
Id. at 4.
9

caution against precisely the campaign occurring in support of MRT – a risky experimental
procedure that separates and patches together building blocks of an embryo heralded by the
media a miracle therapy – wherein the media praises physicians engaging in fertility tourism to
allegedly dodge unnecessary regulations while generating publicity and expanding a highly
profitable commercial market into for patients with infertility.
B. Council of Europe Position on Germline Modification
The Council of Europe has also promulgated several documents pertaining to
prohibitions on germline interventions. The Council of Europe’s Convention on Human Rights
and Biomedicine states “an intervention seeking to modify the human genome may only be taken
for preventive, diagnostic, or therapeutic purposes, and only if its aim is not to introduce any
modification in the genome of any descendants.”45 This Convention clearly demarcates
therapeutic somatic interventions as potentially permissible, but unequivocally distinguishes that
any germline or inheritable modifications are prohibited. Aligned with this prohibition, in 2001
the European Union promulgated a directive on clinical trials that further specified, “No gene
therapy trials may be carried out which result in modifications to the subject’s germline genetic
identity.”46 Both statements prohibit both clinical trials designed to investigate MRT because it
would result in germline modifications.

45

Article 13, Convention on Human Rights and Biomedicine, COUNCIL OF EUROPE (1997),
https://rm.coe.int/CoERMPublicCommonSearchServices/DisplayDCTMContent?documentId=0
90000168007cf98.
46
Article 9, Directive 2001/20/EC, COUNCIL OF EUROPE (2001),
http://ec.europa.eu/health//sites/health/files/files/eudralex/vol1/dir_2001_20/dir_2001_20_en.pdf.
10

C. Comparing U.S. Governance Pertaining to Germline Modification to Other
Nations
Globally, approximately forty countries47 including Canada,48 Germany,49 France,50
Switzerland,51 Sweden,52 and Italy53 have adopted legislation prohibiting germline intervention
on embryos.54 Laws enacted in the aforementioned nations not only prohibit germline or
heritable modification, but such actions constitute criminal violation subject to fines and or
imprisonment. Unequivocally prohibiting and criminalizing an action communicates the
egregiousness, potential for harm, and social unacceptability of such an action in these nations.
Unlike the widespread alarmist rhetoric that the United States is “falling behind” and failing to
invest in promising genomic technologies, these laws demonstrate the opposite: many countries
acknowledge the lure of technology, but renounce risky experiments that cross the historical

47

See Araki & Ishii, supra note 15, at Table S1: Policies on Human Germline Gene Modification
for Reproduction Excluding Reproductive Cloning.
48
Assisted Human Reproduction Act § 5 (2004); Assisted Human Reproduction Act § 60 (2004).
49
Embryo Protection Act, Federal Law Gazette, Part I, No.69 (1990).
50
Research on Embryos, Bioethics Law, Code of Public Health Article L2151-5 (2011);
Absolute Prohibition on Creating Transgenic Embryos and Chimeras, Bioethics Law, Code of
Public Health. Article L2151-2 (2011); see also Sylvain Beaumont & Sandra Tripathi, France’s
Loi du 7 Julliet 2011 Clarifies The Human Embryonic Research System, LIFE SCIENCES
BULLETIN, Fasken Martineau (Aug. 2, 2011), http://www.fasken.com/files/Publication/ad92fa84d869-497e-80d7-071bfef919e5/Presentation/PublicationAttachment/f3b681c6-78fc-4379-aa6d19456049955c/Life%20Sciences%20Bulletin%20-%20Beaumont-Tripathi%20%20August%202%202011.pdf.
51
Article 35, Federal Act on Medically Assisted Reproduction, Federal Assembly of the Swiss
Confederation (1998).
52
See Sections 3-4, The Genetic Integrity Act, Swedish Code of Statutes no.2006:351 (2006).
53
Article 13, Rules of Medically Assisted Procreation, No. 40 (2004).
54
Some laws prohibit germline modification to any embryo, some prohibit modification for
implantable embryos. See also Isasi et al., supra note 15; Anna Zaret, Editing Embryos:
Considering Restrictions on Genetically Engineering Humans, 67 HASTINGS L. J. 1805, 1810-11
(2016).
11

bright line of manipulating future generations.55
Canada’s Assisted Human Reproduction Act in particular contains notable provisions that
prioritize central concepts to guide appropriate application of technology relating to reproductive
and genomic interventions.56 Section 2 of Canada’s Assisted Human Reproduction Act states
that the “health and well-being of future children must be given priority,” and that the Parliament
seeks to uphold the “protection of human health, safety, dignity and rights” relating to the use of
assisted reproductive technologies, and prohibits compensation for oocyte donors due to the
potential for health risks and exploitation.57 Further, Subsection (g) of Section 2 explicitly states
“the integrity of the human genome must be preserved and protected.”58 These provisions
together recognize the commercial nature of technology and declare neither commercial nor
other interests, such as the technological imperative, ought to drive the adoption of technology
and modification of the germline is prohibited.59
In 2015, the National Academy of Sciences, Engineering and Medicine, the Royal
Society, and the Chinese Academy of Sciences sponsored the International Summit on Human
Gene Editing to discuss broader issues relating to gene editing and modification of the

55

The Science and Ethics of Genetically Engineered Human DNA, Hearing Before the
Subcommittee on Research and Technology, 114TH CONGRESS (2015). Rather than discussing
human dignity or risks of technology, attendees at this hearing pled for federal funding, noted the
global market competitiveness, and asserted regulation must not “squelch the science” or the
United States would “fall behind.” Attendees also mischaracterized the experimental nature of
germline modification, asserting that parents merely have a “desire to protect their children” [by
modifying their genomes] and there may be a time when we consider it unethical not to modify
our children’s genomes.
56
Assisted Human Reproduction Act § 2 (2004).
57
Id.
58
Id.
59
Id.
12

germline.60 Though the meeting discussed recent research relating to other genetic modification
technologies such as CRISPR, many of the considerations are also applicable to MRT. The
National Academies Press published a meeting summary that called for a moratorium on clinical
germline modification, noting safety and efficacy issues are unresolved, and such action could
impose irreversible risks and long term harms.61 Commentators at the International Summit also
recognized the potential for economic interests to capitalize on the global nature of science and
technology, where technology adopted in one location prompts international forum shopping. 62
Situating the actions of Dr. Zhang and Dr. Zukin against the backdrop of the global
climate where many nations not only prohibit, but impose criminal penalties for these risky
experiments it becomes exceedingly clear how radical these events were. Numerous scientists,
bioethicists, and policymakers swiftly voiced vehement opposition, asserting that “going rogue”
was “irresponsible and unethical” because it combined reproductive tourism promoting
commercial interests with “highly experimental science.”63 These characterizations stand in stark
contrast to media articles praising Dr. Zhang, decrying slow “progress” in the United States, and

International Summit on Human Gene Editing: A Global Discussion, NAT’L ACAD. OF SCI.,
ENG’G & MED. (2015), https://www.nap.edu/catalog/21913/international-summit-on-humangene-editing-a-global-discussion.
61
Id.
62
Id.
63
Comment on the Use of Mitochondrial Manipulation Techniques by US Scientists in Mexico,
CTR. FOR GENETICS & SOC’Y (Sept. 27, 2016),
http://www.geneticsandsociety.org/article.php?id=9697; Comment on “3-Person IVF”
Procedures Reportedly Conducted in Ukraine, CTR. FOR GENETICS & SOCIETY (Oct. 10, 2016),
http://www.geneticsandsociety.org/article.php?id=9730; 3-Person IVF A Resource Page, supra
note 37; see also Paul Knoepfler, First 3-Person IVF Baby Born Via “Rogue” Experiment in
Mexico Clinic? The Niche (Sept. 27, 2016), https://ipscell.com/2016/09/first-3-person-ivf-babyborn-via-rogue-experiment-at-mexico-clinic/; Pete Shanks, Wrong Steps: The First One From
Three, DECCAN CHRON. (Oct. 2, 2016), http://www.deccanchronicle.com/lifestyle/viral-andtrending/021016/wrong-steps-the-first-one-from-three.html.
60

13

intimating these procedures constitute an effective “treatment, or even cure.”64 Perpetuating such
bias and gross mischaracterization in scientific media deliberately skews the framing of the
discussion as an intentional means to gain favor and direct the outcome. This campaign not only
lacks transparency, but promotes a policymaking process premised upon inaccurate scientific
information and false characterizations of global legal consensus that renders it egregiously
unethical. Furthermore, Dr. Zhang’s actions to evade regulatory structures in the United States
by performing MRT in Mexico were precisely the type predicted by the International Summit,
and will likely continue to occur based on a public statement from the New Hope Fertility Center
branch in Mexico promising plans for more “three-parent babies.”65
IV. United Kingdom’s Process to Permit MRT
In 2013, the Human Fertilisation and Embryology Authority (HFEA) began its
consultation process to consider the process of permitting MRT. The HFEA is the entity in the
U.K. that oversees reproductive technologies such as IVF and commercial surrogacy and
promulgates criteria for licensing fertility clinics.66 During the policymaking process in the
United Kingdom, scientists, bioethicists, and other stakeholders raised concerns about how both
the British media, the U.K. Department of Health, and the HFEA presented MRT to the public.67

Ossola, supra note 6; Michael Le Page, Mexico Clinic Plans 20 “Three-Parent” Babies in
2017, NEW SCIENTIST (Dec. 9, 2016), https://www.newscientist.com/article/2115731-exclusivemexico-clinic-plans-20-three-parent-babies-in-2017/.
65
Id.
66
Castro, supra note 13; 3-Person IVF: A Resource Page, supra note 37; About the HFEA,
Human Fertilisation and Embryology Authority, http://www.hfea.gov.U.K./25.html.
67
See generally Steve Connor, Scientists Accuse Government of Dishonesty Over GM Babies in
Its Regulation of New IVF Technique, THE INDEPENDENT (July 28, 2014),
http://www.independent.co.U.K./news/science/exclusive-scientists-accuse-government-ofdishonesty-over-gm-babies-in-its-regulation-of-new-ivf-9631807.html; Stuart Newman,
Deceptive Labeling of a Radical Embryo Construction Technique, HUFFINGTON POST (Dec. 1,
2014),: http://www.huffingtonpost.com/stuart-a-newman/deceptive-labeling-of-ar_b_6213320.html.
64
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At the start of this initial period of consultation, forty one signatories including notable
bioethicists, scholars, and scientists published a letter to the editor of The Times expressing alarm
over HFEA’s proposal for MRT.68 This letter noted the broad global consensus against germline
interventions, stated MRT would “cross the Rubicon” and open the door to other germline
modifications, and may pose unforeseen consequences.69 The authors also noted the
transnational implications and urged HFEA against acting alone, declaring the U.K. must
consider its “international responsibilities.”70 Despite exceedingly clear widespread opposition
and breach of longstanding international precedent against germline modifications, HFEA
continued its deliberative process.
A. HFEA Review and U.K. Department of Health
In 2014, the HFEA published a Review of the Safety and Efficacy of Methods to Avoid
Mitochondrial Disease Through Assisted Conception (“HFEA Review”).71 The HFEA Review
referenced a provision from an amendment passed in 2008 that defined a “[permitted] egg or
embryo” as one that has been altered through a technique designed to avoid the transmission of
mitochondrial disease.72 Unlike the indicated use under consideration in the United States, the
regulation in the U.K. only pertains to MRT for the purpose of avoiding mitochondrial disease
and the HFEA Review specifies it does not currently encompass treatment for infertility.

The

HFEA Review reflected a favorable option toward MRT, basing its presumptions on measuring
low preliminary levels of carryover maternal mutant mtDNA, asserting the methods of MRT are

68

Letter to the Editor, Alarm Over Genetic Control of Embryos, THE TIMES (March 20, 2013),
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“efficient” and “reassuring.”73 The HFEA Review also characterized that existing animal
models demonstrated “good progress”74 and concluded “the evidence does not seem to suggest
the techniques are unsafe.”75
During this process, the U.K. Department of Health issued several reports and statements
describing the process of MRT that strategically characterized the procedure in a manner to
avoid scrutiny for the crossing the bright line prohibition against germline modifications.76 First,
the U.K. Department of Health conceded that MRT constituted a germline modification, but
argued that it did not pose a genetic modification because there is not an agreed upon definition
of what a genetic modification entails.77 The U.K. Department of Health suggested modifying
mtDNA and performing nuclear genome transfer does not alter the oocyte or embryo’s genetic
information, asserting mtDNA merely functions as batteries of the cell.78 Second, the U.K.
Department of Health extended this presumption by maintaining MRT would not contravene the
Universal Declaration on the Human Genome and Human Rights’ prohibition against germline
interventions because it serves a therapeutic corrective purpose so it does not harm human
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dignity.79 This bizarre twisting of terminology not only distorted the characterization of MRT to
the public, but fueled scientifically incorrect descriptions in British media aimed at garnering
public support.
The HFEA Review acknowledged the potential for complications pertaining to safety
and efficacy, but unilaterally disregarded what the scientific community has described as
numerous substantial barriers.80 For example, the HFEA Review addressed differential
segregation and maternal bottleneck that could result in increasing levels of heteroplasmy during
the offspring’s course of development in different tissues, and increasing levels of heteroplasmy
through subsequent generations.81 In response to this possibility, the HFEA Review responded
“there is little evidence of this occurring.”82 Importantly, HFEA’s evaluation is based on the
premise that PGD testing of the blastocyst (cells in early stages of embryonic development)
constitutes an accurate representation of both lifetime heteroplasmy in all subsequently
developed tissues and health of the eventual offspring.83
The HFEA cited animal studies using macaque models where about half of the macaque
embryos appeared to develop normally as evidence of “good progress” that MRT appeared to
work.84 In response to the half of embryos following MRT that did not develop correctly, HFEA
disregarded these findings, asserting there may be “some differences in embryo development, but
nothing has been found to raise concerns of safety.”85 The HFEA also noted the concern that
there may be incompatibility arising from mixing mtDNA from two sources, but concluded
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mixing two sources of mtDNA would not pose any complications to interaction with nDNA or
cell function.86 As support for its conclusion, HFEA observed that children from mixed race
parents (one source of maternal mtDNA) do not exhibit higher percentages of mitochondrial
disease.87
B. Public Comments in the U.K. Policymaking Process
During this process, the U.K. House of Commons Science and Technology Committee
held a hearing on the scientific evidence for MRT and published written correspondence from
numerous scientists, physicians, bioethicists, and other stakeholders.88 Although a minority of
comments lent support to HFEA’s proposed direction and even asserted it would be unethical not
to use MRT,89 the majority of public comments fervently opposed MRT precisely based on
unsettling and unresolved issues pertaining to evidence for its safety and efficacy.90 A number of
comments highlighted the unpredictability of differential segregation and maternal bottleneck,
asserting that attempting to measure carryover of maternal mtDNA in the blastocyst via PGD
was an ineffective and improper proxy for predicting long term levels of heteroplasmy and health
outcomes.91 Comments also opposed HFEA’s characterization of animal models as successful,
noting that the 52% of animal embryos that did not develop correctly demonstrated chromosomal
abnormalities, and questioned whether these findings may result in unexamined differences in
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the embryos that scientists proclaimed were developing normally.92
In addition to these responses, multiple comments disputed HFEA’s conclusion
pertaining to the compatibility of two sources of mtDNA and epigenetic effects resulting from
transfer of the nuclear genome from one oocyte or embryo to another.93 A number of interested
parties, including the Council for Responsible Genetics, Human Genetics Alert, and several
scientific experts submitted similar assessments noting evidence for extensive communication
between mtDNA and nDNA expression.94 Disrupting mtDNA functioning and cross-talk to
nDNA directly influences DNA methylation and chromosomal gene expression.95 That is,
mitochondria are not merely batteries supplying energy to the cell that can be deftly exchanged,
but part of a complex interwoven system necessary for the entire organism’s subsequent
development.96 These observations also highlighted the unprecedented risks related to embryo
manipulation, noting the more extreme the level of physical manipulation, the higher the
potential for physical damage to the embryo or epigenetic changes resulting from the process of
physical manipulation and the risk for functional and developmental health deficits.97
Notably, these comments independently evaluated the status of scientific evidence
underlying HFEA’s conclusion that the techniques appear “not unsafe” and concluded the
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opposite: these techniques are likely to be unsafe.98 Human Genetics Alert questioned why
HFEA would blatantly dismiss substantial categories of potential risks, alleging its process was
based on “disastrously flawed scientific assumptions,” charged that the public consultation
process was “biased” because HFEA did not accurately describe MRT, and asserted the
amendment lacked public support.99 Cell biologist Professor Stuart Newman reiterated Human
Genetics Alert’s objection to improper framing to the public because HFEA the technology as
“mitochondrial donation.” 100 Newman implored HFEA to appropriately label the technology as
nuclear genome transfer, pointing out this technique creates a child through an evolutionary
unprecedented experiment because it removes 20,000 chromosomes from one ooctye or embryo
and transfer this nDNA into another oocyte or embryo.101 Critics exhorted that “harmful
consequences of these methods could impair entire generations,” and issued proclamations that
HFEA’s conclusions were both “incomplete and unsubstantiated.”102 Reiterating this warning,
cell biologist Professor Paul Knoeplfer proclaimed the U.K. was on the verge of an “historic
mistake.”103
C. The Role of British Media
The press quickly rebounded and parroted the U.K. Department of Health and HFEA’s
strategic framing to garner support for the 2015 amendment to the Human Fertilisation and
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Embryology Act that would expressly regulate MRT.104 Professor Julian Savulescu compared
MRT to a “micro-organ transplantation,” alleging there is “no sound basis to oppose MRT”
because it constitutes a “cure” so infants can be born without mitochondrial disease.105 An
article in the Guardian appealed to the pathos of parental suffering touting MRT as a method to
prevent incurable genetic disease and “[save] families needless misery” over ill-advised
objections of religious groups.106 Both Savulescu and an article in the New York Times chided
opposition to MRT, scoffing that “preventing medical advancement” is so illogical, it could only
be based on being improperly informed.107
These pieces in the media not only reinforced incorrect scientific characterizations set
forth by the U.K. Department of Health and the HFEA, but employed a dangerous precedent of
classifying legitimate scientific dissent supported by credible evidence outside the parameters of
acceptable discussion. Elevating the U.K. Department of Health and HFEA’s presumptions as
sacrosanct is not only scientifically disingenuous, but dangerous to the honesty and transparency
required in the policymaking process.
D. Outcome of the U.K. Policymaking Process and Lessons for the U.S.
In November of 2016, HFEA recommended “cautious use” of MRT subject to a set of
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conditions where individual fertility clinics must apply for a license to conduct the procedure.108
Following HFEA’s decision, the Newcastle Fertility Center announced its intent to submit an
application for a license and begin the process of offering MRT to its fertility patients meeting
the criteria set forth by HFEA.109
A number of key points emerged during the lengthy policymaking process in the U.K.
that provides perspective when considering the process in the U.S. When HFEA and the U.K.
Department of Health initially raised the possibility of MRT, bioethicists, scholars, and scientists
noted MRT would breach the broad global consensus against germline modifications and urged
the government to reconsider. To initially gain favor, the HFEA and the U.K. Department of
Health strategically named the techniques MRT rather than accurately describing it as nuclear
genome transfer. Relabeling a procedure by comparing it to an acceptable practice such as organ
donation or replacing batteries obfuscated the gravity and risk involved. During the consultation
process, numerous scientists provided testimony and correspondence at length relating to safety
and efficacy. These scientists objected to HFEA’s conclusions based on available evidence,
finding not merely a lack of consensus pertaining to safety and efficacy, but that the available
scientific evidence demonstrated how unsafe MRT is. Despite objections based on international
governance, evidence demonstrating insufficient safety and efficacy, and lack of public
consensus, British Parliament passed the amendment that would permit HFEA to license fertility
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clinics to offer MRT reflecting a massive disconnect in the legal, scientific, and policymaking
process.
V. United States Governance and Policymaking Related to MRT
Similar to the United Kingdom, the United States has undertaken steps to begin the
process of permitting MRT. There is currently no legal prohibition against germline
modification in the United States.110 In 2014, the FDA convened meetings to discuss the
medical rationale and scientific evidence pertaining to MRT for both the prevention of
mitochondrial disease and the treatment of infertility.111 In 2015, the White House announced
that germline modifications constituted a line “that should not be crossed at this time”112 and the
NIH issued a statement it would not fund research involving germline modification.113 However,
in 2016, the National Academies of Science, Engineering, and Medicine issued a report (NAS
Report) on the ethical and policy implications of MRT and concluded it is ethically permissible
to conduct clinical investigations subject to a set of conditions.114 Based on another subsequent
report issued by NAS endorsing therapeutic germline modification through gene editing, it
appears likely that the governance climate in the U.S. favors MRT, and any present prohibitions
related to federal funding may potentially be lifted in the future.115
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A. Applicable FDA Regulations to MRT
In the United States, any clinical investigational use of MRT falls under the purview of
the FDA. Under the Public Health Service Act (“PHSA”), the FDA regulates human cell and
tissue products (“HCT/Ps”), which refers to articles “containing or consisting of human cells or
tissues that are intended for implantation, transplantation, infusion, or transfer into a human
recipient.”116 These regulations are designed to prevent contamination and communicable
disease rather than to ensure safety and efficacy.117 They impose several requirements such as
registering the HCT/Ps with the FDA and promulgating standards for Good Tissue Practices,
including monitoring the procedures, facilities, processing equipment, and supplies and reagents
used in the manufacturing process.118 Under the HCT/P system set forth in 21 CFR §1271, the
FDA classifies different types of human cells, tissues, and cellular and tissue-based products into
categories for regulation based on the public health risks they pose: (1) products not subject to
HCT/P regulations, (2) HCT/Ps regulated under Section 361 of the PHSA, and (3) products
posing the most risk that are to be regulated stringently as a biological product or drug.119
In the late 1990s and early 2000s several clinics began to conduct cytoplasm transfers.
These procedures differed from MRT currently under consideration because the procedure
involved injecting cytoplasm from a donor containing mitochondria into the mother’s oocyte and
did not involve nuclear genome transfer.120 Though technically distinct, these procedures
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resulted in the birth of seventeen children, two of whom had chromosomal abnormalities and one
whom had with pervasive developmental disorder.121 Only cursory follow-up has been
conducted on the health of the resulting children, but the incident prompted the FDA to assert its
jurisdiction over this area of reproductive technology.122
In 2001, the FDA expanded its definition of “human cells, tissues, or cellular or tissue
based products” HCT/Ps to include semen or other reproductive tissue.123 This required fertility
clinics handling gametes and reproductive tissue to comply with requirements for laboratory
registration, minimal procedures to screen HCT/Ps for communicable disease, and good
manufacturing procedures.124 FDA considers standard procedures such as IVF “minimal
manipulation” and subject only to the requirements set forth in Section 1271.125
Around this time in 2001, the FDA sent a warning letter to the scientists conducting
cytoplasm transfers, asserting clinical research involving the transfer of genetic material must be
conducted pursuant to an investigational new drug application.126 In 2009, the FDA issued
guidance affirming this position, asserting procedures currently used for MRT including
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maternal spindle transfer and pronuclear transfer that involve the transfer of genetic material
constitute “more than minimal manipulation” and require the investigator to submit an
investigational new drug application.127 Thus, clinical investigation of MRT would require
“submitting preclinical data and information on product safety, details about technique, and
proposed clinical investigation protocols” pursuant to an investigational new drug application.128
If the FDA were to approve MRT and license its use for only one indication such as the
prevention of mtDNA disease, clinics would be able to expand the scope of indications through
off label use for other uses such as infertility and therapeutic energetic correction.129 As with
other drugs and biologics, off label use dramatically expands both the potential market and
opportunity for commercial profit.
B. Federal Funding Considerations
In addition to federal regulations set forth by the FDA, clinical investigation using
embryos would be subject to federal funding restrictions and subject to state laws pertaining to
research on embryos, some of which appear to prohibit MRT.130 At the federal level, the
Dickey-Wicker Amendment prohibits the use of federal funds for research in which an embryo is
created or destroyed.131 However, some state laws as well the Dickey-Wicker Amendment
contain exceptions in circumstances where the research on the embryo would provide benefit to
the embryo or if the investigation is defined as therapeutic research designed to lead to gestation
and birth of that embryo.132 Finally, the Consolidated Appropriations Act of 2016 currently
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prohibits the FDA from using federal funds to consider applications for an exemption for
investigational use of a drug or biological product “in research in which a human embryo is
intentionally created or modified to include heritable genetic modification.”133 Although the
Consolidated Appropriations Act appears to prohibit the FDA from using federal funding to
review applications for MRT, the NAS Report recently questioned whether MRT constitutes
heritable germline modification, asserting it would require additional legal analysis which makes
the application of the spending prohibition uncertain.134
C. FDA Meetings to Discuss Safety, Efficacy, and Risks of MRT
In 2014, the Cellular, Tissue, and Gene Therapies Advisory Committee of the FDA held
a meeting titled “Oocyte Modification in Assisted Reproduction for the Prevention of
Transmission of Mitochondrial Disease or Treatment of Infertility,” (“MRT Meeting”) which
addressed the intersecting regulatory and scientific considerations pertaining to safety and
efficacy of MRT based on available data and the state of scientific knowledge.135 In conjunction
with this meeting, the FDA published a briefing document (“MRT Brief”) on the same
summarizing the proposed methodology and areas of concern pertaining to safety.136
1. Determining Efficacy and Defining Success
During the MRT Meeting, the FDA addressed the patient population and indicators of
how to define success. Significantly, the MRT Meeting not only addressed MRT for the
prevention of mtDNA disease, but also for treating infertility. Unlike other potential clinical
trials where the FDA determines calculations of safety and efficacy for the intended patient, the
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subject would be created using the proposed methodology. Past reports issued by the President’s
Council on Bioethics and the NAS have asserted that because the clinical investigation occurs on
the embryo, it would not constitute human subjects research as defined in the Common Rule.137
Under this interpretation, any research conducted prior to implantation need not meet the
requirements set forth in the Common Rule such as its specific requirements for informed
consent and the provision that the benefits must be greater than the risks as applied to the
resulting child.
Participants at the MRT Meeting posed the question of how to define efficacy, with some
participants proposing that efficacy can be determined from a viable pregnancy.138 During the
course of the meeting, however, commentators noted lack of scientific consensus pertaining to
defining the parameters of efficacy, and some commentators urged testing the blastomere (cells
in early stages of embryonic development) for viability is not indicative of the health of the child
and subsequent offspring.139 One scientist also noted that testing a sample is not indicative of the
rest of the inner cell mass, meaning different levels of heteroplasmy may exist, and even
subsequently develop at varied rates in different tissues though stages of development and the
child’s life.140 Based on those metrics, efficacy could not be determined merely from a viable
pregnancy but instead requires examining the health of the child and potentially the child’s
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offspring. Scientists and scholars have commented on this bind, observing that we simply cannot
know with certainty whether MRT would be safe and effective because germline intervention
necessarily imposes substantial risk that cannot be eliminated.141
2. Current Barriers to Safety and Efficacy in MST and PNT
Throughout the course of the meeting, the participants discussed a number of barriers to
safety and efficacy arising from mitochondrial biology described supra in Section II.
a. Maternal Bottleneck, Segregation, and Heteroplasmy
According to participants at the MRT Meeting, animal models have not sufficiently
addressed maternal bottleneck, where levels of mutant mtDNA can increase from one generation
to the next.142 Currently, it is difficult to predict the child’s pattern of inheritance based on the
mother’s percent of mutated mtDNA. Thus, a mother presenting without mtDNA disease based
on her low level of heteroplasmy could give birth to a child with a high level of heteroplasmy
that reaches the threshold to be affected by mtDNA disease. Furthermore, maternal bottleneck
can increase the percent heteroplasmy in each subsequent generation.143 A blastomere, or even a
child that initially demonstrates low levels of heteroplasmy from mutant mtDNA carryover who
appears healthy may pass on amplified risk to future generations who would present with
mtDNA disease.144 Some evidence exists to suggest these risks would particularly affect female
generations.145 These observations pertaining to maternal bottleneck mirror the shortcomings of
PGD as a method of currently screening embryos at risk for mtDNA disease, and underscore the
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inability to predict efficacy based on testing the blastomere.146 Additionally, even testing adult
tissues may demonstrate no mtDNA mutations, but mtDNA mutations could be present in the
germ cells of the individual and be passed on through reproduction to the subsequent generation,
and increase from one generation to the next.147
Currently, effective methodology does not exist to account for testing the fluid mutations
of mtDNA in every tissue over the human lifespan.148 Following the procedure of MST or PNT,
the combination of maternal mtDNA carried over into the donor oocyte continues to divide and
increase in each cell of the growing organism. Biologist Dr. Shoukhrat Mitalipov, whose lab had
been conducting investigations based on animal models, asserts segregation in tissues drifts
toward homoplasmy, which would result in the donor’s mtDNA dominance.149 Despite
Mitalipov’s testimony at the MRT Meeting declaring favorable genetic drift, this presumption is
not universally shared by other experts.150 According to other research, there is little known
about the dynamic by which mtDNA evolves within an organism, because one haplotype (the
group of genes in mtDNA−here there is the maternal haplotype of mtDNA and the donor
haplotype of mtDNA) could replicate faster than the other, which could result in a dramatic
increase in the level of heteroplasmy.151
Segregation and replication of mtDNA occurs according to its own evolutionary system,
which makes predicting subsequent levels of heteroplasmy difficult.152 Even if segregation
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initially demonstrates favorable drift toward the donor’s mtDNA, these levels may jump
unpredictably, or segregate at different levels in tissues throughout the body.153 Levels of
mtDNA in the child’s blood may reflect a low percent of heteroplasmy, but genetic drift can
cause segregation toward the mother’s mutated mtDNA in specific tissues or organs, wherein the
child may experience diseases arising in those systems.154 Specifically, one study demonstrated
initial carryover rates of maternal mtDNA of 1.2% unexpectedly increased to 53% when
studying embryos in culture, leading one biologist in favor of MRT to admit that “it would defeat
the purpose of doing mitochondrial replacement” and “it is wise not to move forward with this
uncertainty.”155 Finally, segregation occurs throughout the lifespan of the individual which
means low levels of the mother’s mtDNA in the child’s blood or partial tissue testing would also
not reflect the possibility of increasing levels of heteroplasmy later in life resulting in latent
presentation of mitochondrial disease.156 Thus, statements that claim heteroplasmy would not
pose a problem if initial carryover of mtDNA appears unsupported by existing evidence.157
In addition to maternal bottleneck and segregation shifting the percent of mutant mtDNA,
mutations in mtDNA that cause heteroplasmy naturally occur through aging and increases
throughout one’s life.158 In addition to mutated mtDNA, both de novo (new) mutations and
mutations to nDNA occur that can result in mitochondrial dysfunction.159 Some scientists
hypothesize there are naturally occurring levels in heteroplasmy in everyone contributing to
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common disease such as heart disease, diabetes, and neurodegeneration.160 These mutations
suggest two points: first, there are other factors influencing the evolution of mtDNA; and second,
attempting to find a donor without mtDNA mutations would be difficult.161
b. Haplotype Incompatibility
Participants at the MRT Meeting also raised concerns relating to the potential for
incompatibility arising from mixing two haplotypes of maternal mtDNA and donor mtDNA.162
Although proponents of MRT state that haplotype mixing does not appear to result in
abnormalities, these presumptions rest upon extrapolating projections that rely on two parent
scenarios.163 Some scientific evidence suggests that segregation appears affected by genetic
distance between haplotypes and when haplotypes of maternal mtDNA and donor mtDNA are
mixed, reversion toward maternal mtDNA occurs.164 In animal models, mixed mtDNA has
resulted in immune rejection, susceptibility to diseases of metabolism, and deficits in
performance and learning capabilities.165
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c. Cross-talk between mtDNA and nDNA
Contrary to the media representations that mtDNA’s role is negligible except for
unidirectional provision of energy, participants at the MRT meeting as well as substantial
additional evidence demonstrate what scientists refer to as cross-talk, symbiosis, and coevolution between mtDNA and nDNA.166 Mitochondrial DNA not only provide energy, but
control metabolic processes, programs cell growth and apoptosis, and impacts nDNA
expression.167 Scientists have described the interaction between mtDNA and nDNA as a
complex evolutionary model, where the genome should be considered comparable to an
ecosystem where every interconnected element affects the functioning of the whole.168
Mitochondrial DNA not only functions as a source of energy, but affects a wide range of cellular
functioning and how nDNA is expressed.169 Disrupting the cross-talk between mtDNA and
nDNA in animal models results in adverse outcomes and disturbs crucial mitochondrial
processes.170 Current research suggests interference in the communication between mtDNA and
nDNA can negatively affect individual development, behavior, susceptibility to disease, and
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fertility.171 As one scientific article summarized, “perturbation of the mito-nuclear interactions .
. . generally attracts grave consequences.”172
d. Animal and In Vitro Models
Based on the current knowledge of animal models, participants at the MRT Meeting
raised the same concerns as in the U.K. discussions about characterizing the current evidence and
limitations of current studies.173 Proponents have highlighted animal models using a small
population of macaques, finding low initial percentages of heteroplasmy and declaring “positive
results” that the offspring are “healthy.”174 However, participants at the MRT meeting noted
several shortcomings: those studies relied on a small sample and may miss problems that would
arise with a larger sample; they did not perform extensive testing for heteroplasmy throughout
tissues; the studies did not test germ cells for heteroplasmy or assess the health of subsequent
generations; and cautioned that using sample tests for heteroplasmy as a proxy for health may
miss other dysfunction.175
In vitro studies evaluating the development of embryos appeared to raise similar concerns
from participants at the MRT Meeting.176 According to Dr. Paula Amato and colleagues, some
studies demonstrated 50% reduced embryo development following PNT, higher rates of
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abnormal fertilization, and aberrant chromosomal segregation.177 Despite these findings, Dr.
Amato and colleagues presume that the development of the remaining embryos signals viability
and health.178 Participants at MRT Meeting disagreed, and instead suggested the remaining
embryos that survive may also be affected with developmental shortcomings.179 These findings
have led Dr. David King of Human Genetics Alert to conclude the embryos that do survive may
develop subtle latent deficits, and has asserted that presuming the opposite− that embryo survival
equates to safety and efficacy− seems risky.180
3. Risks Arising from Assisted Reproductive Technology, Oocyte Manipulation,
and Epigenetic Impact
In addition facing unpredictability and uncertainty arising from mitochondrial biology,
the participants at the MRT Meeting and additional research have examined background risks
arising from using assisted reproductive technology (“ART”), risks from the process and
procedures involved with MRT, and epigenetic impact on the health of the child.
Numerous studies have assessed the impact of “considerable epigenetic changes” on the
health outcomes of children born through the process of ART.181 According to some figures,
children born through ART have a 30-40% increased rate of major congenital malformations,182
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increased risk of autism,183 more childhood illness,184 a higher occurrence of cardiovascular
conditions,185 and an increased risk of cancer.186
Researchers have hypothesized a number of reasons for such outcomes, including drugs
used by the mother during ovarian stimulation;187 that impaired fertility may signal existing
genetic mutations, in either mtDNA or nDNA, in the mother’s oocytes;188 and the impact of
damage caused to the embryo arising from physical manipulation and the processes used during
ART.189 Current research suggests a correlation between the amount of physical manipulation to
the embryo and level of damage resulting in potentially serious health deficits.190 Physical
damage may result from temperature shifts;191 reagents used and time the embryo spends in
culture;192 destruction to cellular architecture;193 and with MRT, potential for viral contamination
based on a particular virus used during the procedures.194 These factors could result in damage
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to cellular structure, aneuploidy, or disruption of chromosomal segregation and division.195
Some of the elements introduced during MRT such as temperature changes, use of
reagents, and changing the composition of mitochondria through MST or PNT may have an
epigenetic impact on the embryo and modify the expression of nDNA.196 During discussions in
both the U.K. and the U.S., participants described a critical window of vulnerability during
which changes to the embryo will influence long term health outcomes through modifying gene
expression.197 These epigenetic changes could result in “imprinting or programming of future
disease in children.”198
During the closing statements by participants at the MRT Meeting, an overwhelming
number of speakers voiced concern not only that scientific evidence failed to demonstrate safety
and efficacy, but that MRT may never be a viable option based on level of risk involved.199
Participants reiterated there are less risky alternatives to having children, and the current
evidence falls “far short” of showing MRT would be potentially safe and effective.200 Germline
modification by its nature means MRT would pose unprecedented risks to the children born as a
result.201 MRT would impact every cell in the body, and there are no methodologies currently to
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ensure the procedure would not inflict novel abnormalities. 202 Based on available research,
scientists cannot currently predict lifetime safety nor latent effects.203 Such mistakes are both
inevitable and irreversible, which means MRT could potentially not only create a congenitally
impaired child, but introduce those deficits into the germline of all subsequent offspring.204
Indeed, current research suggests disrupting mtDNA through MRT may have the potential to
result in developmental disorders,205 latent fatalities,206 expedited aging,207 increased risk of
cancer,208 as well as unknown abnormalities.209 The weight of the evidence unquestionably
points not merely to insufficient evidence of safety and efficacy, but should raise utmost alarm
for the severity of potentially imposing novel risks. These extensive considerations do not
support the National Academies of Science, Engineering, and Medicine Report’s conclusion that
conducting clinical trials for MRT is ethically permissible.
D. NAS Report on the Ethical Permissibility of MRT
Following the FDA’s MRT Meeting and MRT Brief that cited numerous risks and lack of
evidence pertaining to safety and efficacy, the FDA requested that the National Academies of
Science, Engineering and Medicine develop a consensus report reviewing the ethical, social, and
policy considerations relating to MRT.210 The NAS Report concluded it is ethically permissible
for the FDA to conduct clinical investigations subject to a set of conditions including: (1) Initial
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safety is established and risks to all parties directly involved in the proposed clinical
investigations are minimized; (2) Likelihood of efficacy is established by preclinical research;
(3) Clinical investigations are limited to women who otherwise are at risk of transmitting a
serious mtDNA disease; (4) Intrauterine transfer for gestation is initially limited to male embryos
(but may be extended to females if safe and effective); (5) FDA may consider haplotype
matching as a means of mitigating risk of incompatibilities between mtDNA and nDNA.211
The NAS Report stated its goals are to minimize risks to the future child and ensure
safety and efficacy of clinical interventions.212 Despite setting forth this goal, the substance of
the NAS Report discussion focused on prioritizing novel technological interventions as a means
to advance science and medicine, asserting the FDA should exercise caution but not impose
absolute limits on technology.213 Echoing the position set forth in British media, the NAS
Report maintained that opposition to MRT arises out of unfounded fear, poor understanding of
the science, and an irrational belief that “natural” is necessarily better.214 According to the NAS
Report, parents take steps daily to improve their children through education and using medicine
when children are ill, and categorized MRT as another option for parents to choose on behalf of
their children’s health and well-being.
However, comparing providing an existing child with a proper education against
undertaking an unprecedented experiment to create a child with known risks that contravenes
multiple global legal prohibitions are incommensurate actions. By refusing any absolute limits,
the NAS Report necessarily weighs the scale in favor of finding benefit in the sake of pursing

211

Id. at 10-11.
Id. at 2.
213
Id. at 7.
214
Id. at 89.
212

39

research for its own sake even when serious reservations of safety and efficacy exist. At times,
the notion of progress requires a prudent pause and adherence to limits where technology would
pose grave risk of harm to the intended recipient.
The NAS Report also justified the use of MRT based on longstanding jurisprudence
respecting parental autonomy and procreative liberty.215 In the history of ART, the desire to bear
genetically related children has been prized, and parents have traditionally been provided wide
lenience to pursue their “reproductive projects.”216 However, a number of bioethicists have
observed this right need not be absolute nor demand all technology available without regard to
whether the original conception of procreative liberty even encompasses such a right, or how
exercising that right would impinge upon the rights of the child.217
In a similar manner as the U.K., the NAS Report employed linguistic creativity, asserting
that although MRT is germline modification, it is not heritable because initial transfer for
gestation would be limited to males who would not pass on mtDNA to their children.218
Throughout the NAS Report the NAS took great care to minimize the role of mtDNA, reassuring
that MRT does not “edit genes” and “there is no direct modification of mtDNA”219 because MRT
merely replaces pathogenic mtDNA with unaffected mtDNA.220 Designed to minimize the
impact of MRT as heritable germline modification, this statement is scientifically inaccurate and
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perpetuates misunderstanding. The description minimizing the actual procedure of a nuclear
genome transfer by describing it as switching mitochondria echoes the misleading descriptions
provide by the HFEA and the U.K. Department of Health. Furthermore, all germline
modifications are heritable because changes to the oocyte or embryo globally impact all the
resulting cells, impacting the growth and development of the child and the expression of nDNA,
which is passed on by both males and females.221 This attempt at extricating MRT from the
category of heritable modifications is likely both a move to slowly introduce the concept of
germline modification as well as a carefully executed strategy to assert that current limitations
prohibiting federal funding for heritable germline modifications would not apply to MRT.222
Finally, the NAS Report addressed international treaties and global prohibitions against
germline modification.223 According to the NAS Report, the language set forth in the United
Nations Universal Declaration on the Human Genome and Human Rights declaring that the
genome constitutes “the heritage of humanity” amounts to “vague and aspirational” language,
and the NAS is “not persuaded that MRT should be prohibited based on arguments that the
genome represents the inviolable heritage of humanity.”224 The NAS Report’s blatant disregard
for conclusive positions set forth by the United Nations along with persuasive nonbinding
precedent set forth by the Council of Europe entails the very action cautioned by the UNESCO’s
International Bioethics Committee when it warned of parsing component parts of the genome,
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renouncing limitations, and permitting market forces to stretch the boundaries of permissible
endeavors. Furthermore, the position of UNSECO’s International Bioethics Committee, the
Council of Europe, and criminal prohibitions on germline modification set forth by numerous
nations demonstrates the United Nations’ language constitutes an unwavering and unmistakable
directive rather than “vague and aspirational language.”
VI. Additional Scientific and Ethical Considerations
After reviewing the scientific elements pertaining to safety, efficacy, and risks at the
FDA MRT Meeting and the ethical, social, and policy issues contained in the NAS Report, these
discussions omitted significant additional considerations. First, permitting clinical investigation
of MRT and announcing the ethical acceptability of MRT relies upon expanding the pool of
oocyte donors. Second, discussions at the FDA and in the NAS Report accept proponent’s
medical rationale for MRT for uses such as to treat mitochondrial disease and infertility without
substantive analysis. Each of these points warrants further discussion to consider how clinical
investigation would impact crucial parties involved in the process−potentially a new pool of egg
donors, and whether available evidence supports the findings that MRT constitutes an effective
method to treat mitochondrial disease and infertility.
A. Increasing Oocyte Donation and Risks to Donors
Although limited literature in the area addresses the impact of permitting MRT on oocyte
donors and increasing risk in the pool potential oocyte donors, these considerations were not
mentioned during the FDA MRT Meeting nor in the NAS Report.225 MRT not only poses
significant risks to the child, but because it relies upon oocyte donation, it would require
increasing the number of oocyte donors and compound the current ethical debates pertaining to
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the acceptability of risk and conflicts of interest present in this sector of the fertility industry. 226
Although some scholars reason autonomy and informed consent obviate ethical hesitation, this
conclusion deserves further investigation.227
Every year, millions of women donate oocytes and are generally paid $5,000-$20,000 per
cycle.228 The process of egg donation requires multiple steps, beginning with a medical
screening questionnaire and blood tests to check for infectious disease. If the fertility clinic
selects this egg donor, then the clinic will begin the process of coordinating the donor’s
hormonal cycle with the intended mother’s by starting a ten to twenty one day cycle of a
hormone such as Lupron to suppress ovulation followed by a seven to twelve day regimen of
injections of high doses of follicular stimulating hormones.229 When the donor’s oocytes have
matured, the fertility clinic administers a final injection of human chorionic gonadotropin. After
the injection of human chorionic gonadotropin, the donor undergoes surgery with anesthesia,
where the physician inserts a needle through her vagina to remove the eggs that were
produced.230 Unlike a normal monthly cycle that produces one egg, this procedure generally
produces around ten to twenty eggs or more depending on the amount of fertility drugs the clinic
uses.231
The process of egg donation exposes donors to a number of short term physical risks in
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connection to the fertility drugs used and the surgical process of retrieving the eggs. Adverse
effects from the hormone injections may include pain, nausea, hot flashes, mood swings, hair
loss, depression, bone pain, chronic enlargement of the thyroid, liver dysfunction, and heavy
bleeding.232 Ironically, evidence also suggests hormone injections of Lupron, a drug to suppress
ovulation commonly during the process of syncing the donor’s cycle to the mother’s, can lead to
the donor’s own infertility because it may disrupt long term ovarian function in the donor.233
Drugs used during this process can also result in ovarian torsion, where the ovaries change
position from the drug induced stimulation in a manner that blocks blood flow and twists the
ovary.234 This condition requires medical intervention to remediate and may result in loss of
ovarian function or surgical removal of the ovary.235 The surgical process of egg retrieval carries
risks associated with general surgery such as danger of infection, complications from anesthesia,
and hemorrhage, as well risks related to the process of egg retrieval such as injury to adjacent
areas like the ureter, bladder, or bowel.236
Donors may also experience ovarian hyperstimulation syndrome (“OHSS”), which is
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fluid build-up in the abdomen and chest caused by gonadotropin stimulation of the ovaries.237
Fluid leads to pressure on the diaphragm that causes difficulty breathing and decreases blood
volume. In severe cases, OHSS can lead to kidney damage, blood clotting disorders, stroke, and
death.238 Estimates suggest the majority of women undergoing egg retrieval experience at least
mild OHSS.239 Although the fertility industry has stated complications from donation and OHSS
are rare, such an assertion is not supported by available data.240 Although fertility clinics keep
statistics on pregnancy outcomes, they generally do not keep records on medical complications
associated with the process of donating.241 Recent independent research that studied the
frequency of complications found varying rates of adverse events: approximately thirty percent
of donors suffered OHSS, and between eleven and thirty percent of donors suffered
complications so severe they required hospitalization.242
Despite the American Society for Reproductive Medicine’s claim that there are no long
term adverse risks of egg donation, this statement inaccurately represents both the known and
unknown long terms risks associated with being an egg donor.243 There are currently no
registries tracking either short term or long term donor outcomes, so comprehensive data for all
donors simply does not exist.244 Despite lack of donor wide registries, numerous studies have
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explored the link between different drugs used during the donation process and in numerous
cases found an increased risk for a variety of cancers, including colon, breast, endometrial,
uterine, ovarian cancer as well as malignant melanoma and non-Hodgkins lymphoma.245
Donation may also result in long term compromise of the donor’s own fertility, chronic pelvic
pain and ovarian cysts.246
Critics of the current donation process have noted deficiencies arising from insufficient
informed consent and conflicts of interest inherent in the egg donation process. Despite evidence
demonstrating these short term and long term risks, donors may not even be aware of these risks
when deciding to undergo donation.247 One study found twenty percent of donors were not
aware there were health risks involved, let alone serious complications such as OHSS, loss of her
own fertility, and increased risk of cancer.248 This discrepancy suggests serious deficiencies in
the informed consent process.249 Fertility clinics’ metrics of success hinge upon successful
pregnancies, which also creates an incentive for clinics to increase the dosage of fertility drugs to
produce more eggs in one cycle.250 Although higher doses of drugs will yield more eggs and
benefit the clinic, it also places the egg donor at greater risk of adverse health consequences.251
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Legal scholars assert this creates a system that treats oocyte donors as separate and
fungible producers of raw materials for a lucrative industry.252 If the fertility industry would
accurately disclose and assess risks, this would jeopardize donor willingness and undermine the
supply of raw material upon which fertility clinics rely.253 Discussions that euphemistically refer
to “cytoplasm donors,”254 and swapping out mitochondria obscures the fact that MRT relies on a
supply of eggs that entails potentially serious risks to egg donors, of which they may not even be
aware. Failing to address where the raw materials for MRT originated and focusing solely on
risks to the child skews the risk-benefit ratio of this experimental procedure. Thus, even those
who believe MRT in potential benefit to the child must also evaluate whether this benefit is
justified at the expense of placing a pool of women’s health at risk for the “reproductive
projects” of third parties.255
B. Evaluating the Medical Rationale of Using MRT to Treat Mitochondrial Disease
and Infertility
1. Sources of Mitochondrial Dysfunction
In addition to the risk profile for MRT, it is crucial to analyze whether MRT would
effectively and sustainably address causes of mitochondrial dysfunction. As stated in Section II,
dysfunction may result from either mtDNA mutations or nDNA mutations. Eighty percent of
mitochondrial dysfunction arises from nDNA mutations for which MRT would not address.
Mitochondrial DNA mutations may either be maternally inherited or arise de novo, as new
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mutations. Recent evidence suggests that a variety of environmental factors induce de novo
mutations. Mitochondrial dysfunction is not only a cause of rare fatal disease, but also has been
implicated as a factor in the development of common diseases, such as neurodegenerative
disease, cancer, diabetes, cardiovascular disease.256 Public health researchers hypothesize that
the rising rates of chronic and debilitating disease are a product of environmentally mediated
epigenetic damage to our mitochondria.257 Changes in mitochondrial integrity appear to
influence a number of diseases, more than the traditionally defined classes of maternally
inheritance of mtDNA disease and nDNA mitochondrial disease.
Mitochondria undergo rapid development called mitochondrial biogenesis during
embryonic and fetal development, and continue to replicate throughout one’s lifetime. During
this critical window of early development, altered maternal mitochondrial function directly
impacts fetal development.258 If mitochondria are damaged during these early stages, scientists
believe the mtDNA deficiencies will continue to replicate during the growth of the organism.259
Mitochondria undergo continual growth and repair throughout the life cycle of the organism, but
if the cell’s repair mechanisms cannot keep pace with external assaults that induce these changes,
cumulative damage will eventually manifest phenotypically in a disease state.260
In the course of one’s life mitochondria are “on the frontline of cellular response to the
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environment.”261 Recent research demonstrates how environmental factors induce epigenetic
changes in mitochondrial activity that can also lead to alternation in nDNA.262 A variety of
environmental agents, including pesticides,263 heavy metals,264 antibiotics,265 pharmaceutical
drugs,266 environmental toxicants such as dioxin267 and Bisphenol A268 can all exert changes to
mitochondrial integrity and development. Over time, exposure to mitochondrial disruptors
damages the mitochondria and impacts the resulting health of the individual. As discussed in
Section II, proper functioning of each cell and the organism as a whole relies on cross-talk
between mtDNA and nDNA. Environmentally mediated mtDNA damage undermines
bidirectional cross-talk and interferes with nDNA repair pathways, which can influence nDNA
methylation and produce epigenetic changes in the expression of nDNA.269 When accumulations
of mtDNA damage and nDNA damage reaches a particular threshold, this manifests as common
diseases.270
This research suggests that even presuming the initial procedure of MRT could ever be
safe and effective, it would not address underlying causes of de novo mtDNA mutations nor de
novo nDNA mutations that phenotypically present as disease. These findings have several
implications for the long term safety and efficacy of MRT over the course of the child’s life.

261

Lambertini & Byun, supra note 257.
Id.
263
Meyer, supra note 160, at 8; Paraskevaidi, supra note 260, at 1.
264
Id.; Brunst, supra note 258, at 982-983.
265
Sameer Kalghati et al., Bactericidal Antibiotics Induce Mitochondria Dysfunction and
Oxidative Damage in Mammalian Cells, 5 SCI. TRANSLATIONAL MED. 1 (2013); Norman
Moullan et al., Tetracyclines Disturb Mitochondrial Function Across Eukaryotic Models: A Call
for Action in Biomedical Research, 10 CELL REPS. 1681 (2015).
266
Meyer, supra note 160 at 3-4; Paraskevaidi, supra note 260, at 3-4.
267
Meyer, supra note 160, at 3-4.
268
Brunst, supra note 258, at 983.
269
Meyer, supra note 160, at 9.
270
Id. at 3-4; Paraskevaidi, supra note 260, at 2-4.
262

49

First, even if MRT could be safe and effective in principle (a hypothesis that is currently
unsupported), exposure to mitochondrial disruptors during biogenesis and over the course of the
child’s life has the potential to undo theoretical mitochondrial correction as damage accumulates.
Based on scientific concerns related to cross-talk between mtDNA and nDNA, this also raises
questions of whether disrupting the naturally occurring cross-talk would have negative
implications for the mitochondria’s evolutionary ability to adapt to the influence of
mitochondrial disruptors.271 Finally, this area of research demonstrates that rare fatal disease
arising from mitochondrial dysfunction merely constitutes the tip of the iceberg. Promoting
MRT as a viable option distracts from the heavy burden of environmentally mediated mtDNA
and nDNA damage quietly influencing the rates of common and chronic disease. Recognizing
and reducing these exposure levels should constitute the focus of the inquiry, along with
concurrent low risk interventions such as exercise and dietary measures, which have been shown
to enhance mitochondrial function. 272
2. Causes of Infertility
The FDA MRT Meeting also considered the possibility of clinical trials to explore using
MRT to treat infertility, and some have suggested treating infertility constitutes the end goal.273
Though the NAS Report limited its recommendation that the FDA limit applications to treatment
of mtDNA disease, the FDA is not bound by NAS’s recommendation. Furthermore, even if the
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FDA were to approve an investigational new drug application related to MRT, the fertility clinic
could subsequently use the approved MRT procedure off label for infertility and other purposes.
Investigating the medical rationale of using MRT to treat infertility raises a similar set of
findings with research demonstrating that rising rates of impaired fertility are likely due to a
variety of complex environmental and lifestyle causes including aging, not inherent genetic
flaws.274
A portion of infertility stems from aging, and as one gynecologist observed, trying to
change biology is “incredibly difficult and expensive to alter.”275 Popular media articles and
scholars have questioned the social messaging behind the cultural phenomenon of delaying
motherhood, asking why addressing age related reproductive complications and limitations have
become taboo.276 During the FDA MRT Meeting, participants discussed a number of age related
biological changes such as diminished ovarian function, risk of aneuploidy, genetic segregation
errors, and oocyte structural defects.277 If aging increases the risk of aneuploidy or mutations to
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nDNA contained in maternal oocytes, MRT would not address these concerns because the
procedure transfers nDNA from the mother to the donor.278
In addition to age, research suggests lifestyle choices can directly impact both female and
male fertility outcomes. Factors such as smoking, alcohol use, diet, and sedentary lifestyle have
been shown to negatively correlate to fertility outcomes.279 Some promising research suggests
positive effects of dietary changes and moderate exercise as an avenue to improve fertility.280
Despite these potential causes, infertility is dramatically rising in the population of young
adults in their twenties which has led researchers to investigate additional causes. Research
implicates a variety of environmental toxicants including pesticides, PCBs, phthalates, parabens,
and Bisphenol A that are present in our daily environment and act as endocrine disrupting
chemicals (EDCs) contributing to rising rates of impaired fertility.281 In 2012, the World Health
Organization and the United Nations Environment Program published a report, “State of the
Science on Endocrine Disrupting Chemicals” on the impact of EDCs on human reproduction.282
Currently, there are eight hundred chemicals that are known or suspected to be capable of
interfering with human reproduction.283 Exposure to EDCs can interfere with hormone
synthesis, conversion, and signaling, which can impair growth throughout the life cycle and
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reproductive capability.284
Scientists describe a period called the critical window of development during gestation
and early infancy, during which exposure to toxicants can alter normal development and
manifest in acute or long term health effects.285 During fetal development, the brain and fetal
tissue undergo rapid development along a specific pathway.286 Any exposure to toxicants during
this crucial stage could halt or alter the normal course of proper hormone signaling and fetal
tissue differentiation leading to long lasting and permanent health deficits.287 These deficits may
manifest through a number of avenues in females including ovarian dysgenesis, premature
ovarian failure, anovulation, and irreversible morphological abnormalities in the human
reproductive tract.288 Importantly, an extensive body of research demonstrates both females and
males are affected by rising rates of infertility.289 In males, the impact of EDCs may result in
low testosterone, a decrease in semen quality, reduction in sperm, and deficiencies in sperm
motility, disruption of testicular development, and abnormalities of the male reproductive
tract.290
Exposures to EDCs during the critical window and throughout the course of one’s life
have the potential to exert epigenetic changes not only to the individual’s somatic cells, but also
to the germ cells.291 This means EDCs are not only changing the individual’s reproductive
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capacities, but also transmitting altered epigenetic marks to subsequent generations and
potentially compromising the offspring’s fertility as well.292
As a whole, this research suggests that the medical rationale of using MRT to treat
infertility contains numerous flaws. Even presuming MRT could ever be safe and effective, it
fails to address impaired fertility that could be prevented through social policy movements that
encourage reproduction during biologically viable years and lifestyle modifications that support
fertility potential. MRT also would not address the various deficiencies in female reproductive
capacity such as reproductive tract abnormalities or insufficient ovarian reserve. MRT would
also not address any of the growing concerns related to male infertility. Scientific research in
this area suggests a need to systematically address the underlying factors contributing to
population level fertility impairment.
C. Assessing the Potential for Market Expansion
After deconstructing the medical rationale, proponents’ claims that MRT could treat
mitochondrial disease and infertility become less compelling. This raises questions of why
proponents would aggressively push a highly risky experimental technology. Developing MRT
to offer as the newest option in the treatment of infertility holds substantial value for industry
revenue and commercial expansion, both domestically and as a means to increase the U.S.
fertility industry’s global market share.293
Statistics vary, but according to the Centers for Disease Control, approximately twelve
percent of couples in the U.S. suffer from impaired fecundity, defined as the inability to get
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pregnant or carry a baby to term.294 The World Health Organization evaluated global rates of
infertility, finding up to one quarter of couples of childbearing age suffer from infertility. 295 In
the U.S., 62 million women of childbearing age are infertile and 7.4 million women seek fertility
services during their life.296 These figures translate into a lucrative industry and “sprawling
commercial enterprise,”297 estimated to be between $3 to 4 billion dollars in the United States,
with demand growing approximately ten percent annually.298
Rising rates of impaired fertility combined with the promise of a genetically related child
have produced a booming market. Having a genetically related child satisfies a deeply held
primal desire, but as legal scholar Lisa Ikemoto observed, industry’s focus on emotional stories
“is compelling because it is real” but it “elides the commercial nature of the practice.”299
Focusing on the pathos of parental yearning distracts from the consumerism, including how
potential parents also constitute vulnerable participants in their quest for parenthood.300
Historian Nathaniel Comfort maintains prioritizing the technological imperative and mastery of
science over nature categorizes emerging technology as a “humane” option for medical suffering
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offered with a “veneer of benevolence.”301 Yet Comfort notes viewing new technology in this
manner fails to situate it within the broader context of a free market system that brutally
capitalizes on the newest technology, at times at the expense of those who seek it. 302
We must be cautious of the commercial market driving the adoption of new technology
such as MRT, because the market prioritizes expansion and profit increase as a primary goal,
which creates a conflict of interest with parents, children, and egg donors in MRT.303 Minimal
regulation combined with a high demand for services means the ART industry has little incentive
to collect and analyze important data related to risk, outcomes, and efficacy beyond basic
statistics related to viable pregnancies.304 This shifts external costs related to latent risks and
long term harm onto parents, donors, and children.305 Unlike other classes of physicians who are
passive providers, the fertility industry constitutes influential stakeholders where the physicians
themselves consistently push for implementing risky experimental techniques as a means of
expanding and increasing their market position.306 If the fertility industry offers MRT in the U.S.
pursuant to an FDA submission, this provides the imprimatur of safety and efficacy, even though
the procedure may indeed pose long term and latent risks to the child and the child’s offspring.
Alternatively, the fertility industry may opt to forgo pursuing an investigational new drug
submission but continue to offer MRT as a service the clinic coordinates to perform in another
country.
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Permitting, or even insisting, that individuals have access to risky experimental
reproductive techniques has the potential to increase reproductive tourism into the U.S. as
destination point for MRT.307 Legal scholars have described how the convergence of
globalization and the fertility market has resulted in potential parents crossing borders, seeking a
country that permits them to fulfill their parental desire.308 Restrictions in some countries have
led to strategic jurisdictional forum shopping, precisely illustrated by the example of Dr. Zhang.
Potential parents willing to travel great lengths may seek out niche markets that offer what
appear to be the newest and best products and services in an attempt to achieve a pregnancy, or
even elect to use MRT as an energetic corrective preventive practice against aging, obesity, and
common disease in the future child.309
VII. Recommendations
Promoting MRT as a method to assist suffering potential parents fails to acknowledge the
substantial weight assigned to scientific innovation and commercial profit incentives driving the
scientific and fertility industry. This framing not only lacks transparency, but appears ethically
troublesome based on the concerted effort during the policymaking process to dismiss the risks
involved in MRT and modifying the human germline.310 As one bioethicist questioned, “Who is
applying the brakes? Private entities are profit driven, which is the last question we should
consider when altering the human race.”311 The U.S. appears poised to not only to accept
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inflated promises of MRT, but to do so through a policymaking process that provided the
appearance of deliberation while issuing conclusions against the weight of the scientific
evidence. This sets a dangerous precedent, where implicit prioritization of scientific exploration
and commercial interests directs governance outcomes in a manner that implicitly subverts
considering risks to human health. In this instance, the weight of the scientific evidence not only
suggests creating children through MRT may not be safe or effective, but that the procedure may
impose new health deficits such as an increased risk of developmental disorders, latent fatalities,
expedited aging, cancer, and congenital abnormalities.
Although some appear resigned to the power of these “baby markets,”312 I assert we have
a duty to use federal regulation as a mechanism to insulate parents, donors, and children from
substantial risks inherent in MRT as well as new technological iterations that promise to correct
genomic flaws by prohibiting modification of the human germline. Commercial and scientific
interests have painted a false double bind: regulation that entails callous prohibitions stifling
innovation to that could otherwise help parents have healthy children, or an unhampered free
market wherein the fertility industry can produce miracles. Confined to the impossible choices
in this narrative blocks us from considering the crucial questions raised here: such as whether the
scientific risks mirror the policymaking outcome; why the discussion glosses over risks to oocyte
donors; how the science fails to support the medical rationale for MRT; and the
inappropriateness of permitting commercial motivations to drive the adoption of MRT.
Rather than prioritizing scientific ingenuity and economic profit, the U.S. and other
nations have a duty to enact measures that discourage risky experimentation on future
generations through MRT and other forms of germline modifications. I affirm the proposition
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that future generations have a right to an “untampered genome.” 313 I further assert that each
individual has a human right to be born without intentional germline interventions, and we have
an ethical duty to investigate and mitigate sources that threaten the integrity of our health. This
duty encompasses a diligence to properly situate and analyze whether proponents’ medical
rationale matches available evidence or constitutes a strategic appeal to our pathos. This stance
against MRT and other germline interventions coincides with the scientific opinion that our
inability to accurately predict the outcomes of potential interventions means germline
modifications including MRT should not be permitted.314 Germline interventions pose
significant risk and carry the threat of unintended consequences that are both irreversible and
permanent.315 The consensus against germline modifications set forth by UNESCO’s
International Bioethics Committee, the Council of Europe, and numerous other nations should
remain intact to protect the health of future generations.
New regulations enacted in other nations should affirm this prohibition through
unambiguous legislative measures. At the federal level, nations should not rely on funding
restrictions, but enact criminal prohibitions for human germline modification of human embryos.
These statutes should prohibit the creation of embryos with germline modifications for
implantation and include additional mechanisms to dissuade implantation. Nations should
recognize the transnational nature of this research and the convergence of forum shopping and
reproductive tourism. As a mechanism to deter avenues of legal circumvention through
reproductive tourism, nations should include prohibitions on recruitment of potential patients for
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impermissible procedures to create embryos with germline modifications, whether through MRT
or another procedure, performed in another nation. These laws could also include a prohibition
on the import and export of unauthorized human embryos for implantation. The statute should
specify explicit criminal penalties that would reflect the gravity for potential harm of
experimenting on future generations.
VIII. Conclusion
UNESCO’s International Bioethics Committee cautioned against a number of elements
that appear to be driving the shift in U.S. policy to permit MRT. Proponents of MRT employed
reductionist explanations and simplified mitochondria’s function, belying its complex
evolutionary role, its impact on nDNA expression, and dismissed extensive doubts in the
scientific community pertaining to safety and efficacy. Media articles in the U.S. praised Dr.
Zhang for traveling to Mexico to perform MRT as a “therapy” to “save lives” and circumvent
FDA jurisdiction. These actions directly contravened the International Bioethics Committee’s
directives for the media to avoid sensationalist journalism and renounce regulatory
circumvention. During FDA meetings to discuss MRT to treat mitochondrial disease or
infertility, many participants concluded the evidence falls “far short” of showing MRT could be
safe and effective and asserted MRT could induce new permanent and irreversible health deficits
in the child, in addition to existing risks arising from ART. MRT would also require increasing
the pool of oocyte donors, which imposes potentially serious health consequences such as OHSS,
impaired fertility, and increased risk of cancer on a class of women in exchange for payment to
satisfy the reproductive projects of third parties. These risks pose significant burdens on both
future children and oocyte donors. Furthermore, analysis of the medical rationale reveals MRT
would not address a substantial portion of conditions related to mitochondrial dysfunction and
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the complex factors influencing rising rates of infertility. The NAS Report’s conclusion that
conducting clinical investigations for MRT is ethically permissible is unsupported by the weight
of the evidence and appears to prioritize the technological imperative and its potential to grow
the U.S. global market share in novel fertility industry options.
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